uniQure N.V. Restricted Share Unit Agreement Granted Under 2014 Share Incentive Plan, As Amended and Restated NOTICE OF GRANTRestricted Share Unit Agreement • March 15th, 2017 • uniQure N.V. • Pharmaceutical preparations
This Restricted Share Unit Grant Agreement (this “Agreement”) is made as of the Grant Date between uniQure N.V., a public limited company incorporated under the laws of the Netherlands (the “Company”) and the Participant.
uniQure N.V. Share Option AgreementShare Option Agreement • March 15th, 2017 • uniQure N.V. • Pharmaceutical preparations
EMPLOYMENT AGREEMENTEmployment Agreement • March 15th, 2017 • uniQure N.V. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is entered into and effective as of this 9th day of December, 2014 (the “Effective Date”), by and between uniQure, Inc., 113 Hartwell Avenue, Lexington, MA 02421, on behalf of itself and any and all of its affiliates (together, the “Company”) and Matthew Craig Kapusta, 53 Greenfield Avenue, Saratoga Springs, NY 12866 (“Executive”).
LEASE FOR OFFICE SPACELease Agreement • March 15th, 2017 • uniQure N.V. • Pharmaceutical preparations
Model adopted by the Real Estate Council of the Netherlands (Raad voor Onroerende Zaken, ‘ROZ’) on 30/01/2015 and filed with the registry of the District Court of The Hague on 17/02/2015 and registered there under number 15/20, also published on the website www.roz.nl.
uniQure N.V. Share Option Agreement Granted Under 2014 Share Incentive Plan, Amended and Restated effective as of June 15, 2016Share Option Agreement • March 15th, 2017 • uniQure N.V. • Pharmaceutical preparations
uniQure N.V. Performance Share Unit Agreement Granted Under 2014 Share Incentive Plan, Amended and Restated effective as of June 15, 2016 NOTICE OF GRANTPerformance Share Unit Agreement • March 15th, 2017 • uniQure N.V. • Pharmaceutical preparations
This Performance Share Grant Unit Agreement (this “Agreement”) is made as of the Grant Date between uniQure N.V., a public limited company incorporated under the laws of the Netherlands (the “Company”) and the Participant.
CONSULTANCY SERVICES AGREEMENTConsultancy Services Agreement • March 15th, 2017 • uniQure N.V. • Pharmaceutical preparations
Forbion Capital Partners Management Services B.V. a private limited liability company having its registered office at Gooimeer 2-35, 1411 DC Naarden, the Netherlands, (“Consultant”), and
UNIQURE SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 15th, 2017 • uniQure N.V. • Pharmaceutical preparations
THIS SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT is made and dated as of May 6, 2016 and is entered into by and among (i) UNIQURE BIOPHARMA B.V., a private limited liability company incorporated and existing under the laws of the Netherlands, having its corporate seat at Amsterdam, the Netherlands and registered at the trade register of the Chamber of Commerce for Amsterdam under number 34275365 (“uniQure Bio”), (ii) UNIQURE, Inc., a Delaware corporation (“US Borrower” and together with uniQure Bio hereinafter collectively referred to as “Borrower”), (iii) UNIQURE IP B.V., a private limited liability company incorporated and existing under the laws of the Netherlands, having its corporate seat at Amsterdam, the Netherlands and registered at the trade register of the Chamber of Commerce for Amsterdam under number 34275369 (“uniQure IP”), (iv) each of the subsidiaries of uniQure identified on the Schedule 1 hereto and the signature pages hereof (“uniQure Subsidiaries”), (v) U
March 14, 2017 Matthew Kapusta Chestnut Hill, MA 02467 Dear Matt:Employment Agreement • March 15th, 2017 • uniQure N.V. • Pharmaceutical preparations
We make reference to the employment agreement dated December 9, 2014, between uniQure, Inc. (together with all of its affiliates, the “Company”) and you (the “Employment Agreement”), by which you have served as Chief Financial Officer of the Company; and to the letter agreement dated October 19, 2016 setting out your compensation arrangements in the role of interim Chief Executive Officer.
